Home/Pipeline/Surlorian

Surlorian

Heart Failure

Phase 2Active

Key Facts

Indication

Heart Failure

Phase

Phase 2

Status

Active

Company

RyCarma Therapeutics

About RyCarma Therapeutics

RyCarma Therapeutics is pioneering first-in-class therapeutics targeting ryanodine receptors (RyRs), a fundamental pathway in calcium signaling implicated in serious muscle diseases. Built on decades of foundational research from founder Dr. Andrew Marks, the company's platform has produced Rycals®, small molecules designed to repair dysfunctional RyRs and modify disease progression. The company is advancing its lead candidate, Surlorian, for heart failure and has programs for RYR1-related myopathies, leveraging prior Phase 2 clinical experience with an earlier Rycal molecule. With a seasoned leadership team and an exclusive license from Columbia University, RyCarma is positioned to address high-unmet-need conditions where current treatments are largely symptomatic.

View full company profile

Therapeutic Areas

Cardiovascular Musculoskeletal

Other Heart Failure Drugs

Drug	Company	Phase	Status
Cardiac Cell Therapy Program	StemCardia	Pre-clinical	Active
NTP42	ATXA Therapeutics	Preclinical	Platform potential identified
Heart Failure Trial	Clinical Investigation Specialists	Not Specified	Actively Recruiting
INPEFA (sotagliflozin)	Lexicon Pharmaceuticals	Approved	Commercial
MyCardia™	Avery Therapeutics	Pre-clinical	Active
Cardiac Assist Device	Second Heart Assist	Pre-clinical	Active
Isosorbide Dinitrate/Hydralazine HCl Tablets	i3 Pharmaceuticals	Approved	Active
TLT-101	TikkunLev Therapeutics	Pre-clinical	Active
Undisclosed Heart Regeneration Program	Animatus Biosciences	Pre-clinical	Active
AFteR Registry	Occlutech	N/A (Registry)	Active
biotx.ai Target Discovery Collaboration	HeartBeat.bio	Pre-clinical	Active
Coronary Sinus Reduction	Shockwave Medical	Unknown	Active